- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Breakthrough Therapy Designation for Keytruda in advanced colorectal cancer
3 November 2015 • Author: Victoria White
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Merck’s Keytruda (pembrolizumab) for the treatment of patients with microsatellite instability high (MSI-H) metastatic colorectal cancer.
This is the third Breakthrough Therapy Designation granted for Keytruda. The drug was previously granted breakthrough status for advanced melanoma and advanced non-small cell lung cancer (NSCLC).
“We are committed to understanding the full potential of Keytruda to help patients with a broad range of difficult-to-treat cancers,” said Dr Roger M. Perlmutter, president, Merck Research Laboratories. “The data investigating the use of Keytruda in patients with advanced colorectal cancer whose tumours have substantial evidence of mismatch DNA repair defects have been encouraging, and we appreciate the opportunity that this FDA Breakthrough Therapy Designation provides us to accelerate our effort to bring Keytruda to these patients.”
New designation based on a Phase 2 study evaluating Keytruda in cancers with microsatellite instability
The Breakthrough Therapy Designation in advanced colorectal cancer is based on data from a Phase 2 study evaluating the activity of Keytruda in cancers with microsatellite instability, a well-established feature seen in cells with certain types of DNA repair defects.
Testing tumours for microsatellite instability can identify patients with defective DNA mismatch repair (MMR) systems. DNA MMR is a process that permits cells to recognise and repair genetic mismatches generated during DNA replication. A defective MMR system allows mismatch mutations to persist. The average tumour has dozens of mutations; however tumours with DNA MMR deficiency may harbour thousands, especially in regions of repetitive DNA known as microsatellites. Tumours that are found to have mutations in select microsatellite sequences, called microsatellite instability (MSI), are considered DNA MMR-deficient. These tumours are referred to as being “MSI high.” Overall, DNA MMR-deficiency is present in approximately 15-20 percent in Stage II disease, 10 percent in Stage III disease and approximately 5 percent or less in Stage IV disease. In colorectal cancers, MMR-deficiency is seen in approximately 15-20 percent of non-hereditary colorectal cancers and in most hereditary colorectal cancers associated with Lynch Syndrome.
Merck is conducting a Phase 2 registration study (KEYNOTE-164) to evaluate the efficacy and safety of Keytruda based on microsatellite instability status in patients with previously treated advanced colorectal cancers, and is also planning a Phase 3 study (KEYNOTE-177) in a treatment naïve patient population.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics